ethyl 4-chloro-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrrolo[2,3-b]pyridine-5-carboxylate | 1039741-37-1

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡咯并吡啶类
• 英文名称: ethyl 4-chloro-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrrolo[2,3-b]pyridine-5-carboxylate
• 英文别名: ethyl 4-chloro-1-{[2-(trimethylsilyl)ethoxy]methyl}-1H-pyrrolo[2,3-b]pyridine-5-carboxylate；ethyl 4-chloro-1-(2-trimethylsilylethoxymethyl)pyrrolo[2,3-b]pyridine-5-carboxylate
• CAS: 1039741-37-1
• 化学式: C₁₆H₂₃ClN₂O₃Si
• 分子量: 354.909
• InChiKey: UZWJYBAZBNZRNW-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.18
• 重原子数：
  23
• 可旋转键数：
  8
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  53.4
• 氢给体数：
  0
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  ethyl 4-chloro-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrrolo[2,3-b]pyridine-5-carboxylate 在 水 、 sodium carbonate 、 N,N-二异丙基乙胺 、 三氟乙酸 、 N-[(dimethylamino)-3-oxo-1H-1,2,3-triazolo[4,5-b]pyridin-1-yl-methylene]-N-methylmethanaminium hexafluorophosphate 、 sodium hydroxide 作用下， 以 四氢呋喃 、 N-甲基吡咯烷酮 、 甲醇 、 二氯甲烷 、 乙腈 为溶剂， 反应 50.08h， 生成 N-((3R,5S)-5-methylpiperidin-3-yl)-5-(2-methylpyrimidin- 4-yl)-1H-pyrrolo[2,3-b]pyridin-4-amine
  参考文献：
  名称：

  [EN] SUBSTITUTED PYRROLOPYRIDINES AS JAK INHIBITORS
  [FR] PYRROLOPYRIDINES SUBSTITUÉES EN TANT QU'INHIBITEURS DE JAK

  摘要：

  本发明涉及具有化学式（I）-（IV）结构的新吡咯吡啶化合物，其中R基团，A、B、C、D和n的定义如详细说明中所述，以及这些化合物及其应用作为治疗疾病的药物。还提供了用于治疗疾病如瘙痒症、脱发、雄激素性脱发、斑秃、白癜风和牛皮癣的方法，用于抑制人类或动物主体中JAK激酶活性。

  公开号：

  WO2020223728A1
• 作为产物：
  描述：

  4-氯-1H-吡咯并[2,3-b]吡啶-5-羧酸乙酯 、 2-氯乙基三甲基硅烷 在 sodium hydride 作用下， 以 N,N-二甲基甲酰胺 、 mineral oil 为溶剂， 反应 1.5h， 以97%的产率得到ethyl 4-chloro-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrrolo[2,3-b]pyridine-5-carboxylate
  参考文献：
  名称：

  Discovery of 3,6-dihydroimidazo[4,5-d]pyrrolo[2,3-b]pyridin-2(1H)-one derivatives as novel JAK inhibitors

  摘要：

  Because Janus kinases (JAKs) play a crucial role in cytokine-mediated signal transduction, JAKs are an attractive target for the treatment of organ transplant rejection and autoimmune diseases such as rheumatoid arthritis (RA). To identify JAK inhibitors, we focused on the 1H-pyrrolo[2,3-b]pyridine derivative 3, which exhibited moderate JAK3 and JAK1 inhibitory activities. Optimization of 3 identified the tricyclic imidazo-pyrrolopyridinone derivative 19, which exhibited potent JAK3 and JAK1 inhibitory activities (IC50 = 1.1 nM, 1.5 nM, respectively) with favorable metabolic stability. (C) 2015 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2015.05.028

文献信息

• CONDENSED PYRROLOPYRIDINE DERIVATIVE
  申请人：Shirakami Shohei

  公开号：US20120034250A1

  公开（公告）日：2012-02-09

  [Problem] The present invention provides a condensed pyrrolopyridine derivative which is useful as an active ingredient for a pharmaceutical composition, in particular, a pharmaceutical composition for preventing or treating diseases caused by undesirable cytokine signal transduction or diseases caused by abnormal cytokine signal transduction. [Means for Solution] The present inventors have extensively studied a compound having a JAK inhibitory action, and as a result, they have found that a condensed pyrrolopyridine derivative which is the compound of the present invention has an excellent JAK inhibitory action, and is therefore useful as an agent for preventing or treating diseases caused by undesirable cytokine signal transduction or diseases caused by abnormal cytokine signal transduction, thereby completing the present invention.

  本发明提供了一种浓缩的吡咯吡啶衍生物，可用作制药组合物的活性成分，特别是用于预防或治疗由不良细胞因子信号传导或异常细胞因子信号传导引起的疾病的制药组合物。本发明的解决方案是，本发明的发明者广泛研究了一种具有JAK抑制作用的化合物，结果发现，本发明的一种浓缩的吡咯吡啶衍生物具有优异的JAK抑制作用，因此可用作预防或治疗由不良细胞因子信号传导或异常细胞因子信号传导引起的疾病的药剂，从而完成了本发明。
• [EN] SUBSTITUTED SULFONAMIDE PYRROLOPYRIDINES AS JAK INHIBITORS<br/>[FR] PYRROLOPYRIDINES DE SULFONAMIDE SUBSTITUÉES SERVANT D'INHIBITEURS DE JAK
  申请人：ACLARIS THERAPEUTICS INC

  公开号：WO2021022178A1

  公开（公告）日：2021-02-04

  The present invention relates to new sulfonamide pyrrolopyridine compounds and compositions useful in the treatment of JAK-mediated conditions having the structures of Formula (I), wherein the R groups are as defined in the detailed description. Methods of inhibition of JAK kinase activity in a human or animal subject are also provided. Exemplary indications treated by inhibition of JAK kinase activity include, but are not limited to, inflammatory bowel disease, Crohn's disease, ulcerative colitis, irritable bowel syndrome, and Celiac disease.

  本发明涉及新的磺胺基吡咯吡啶化合物和组合物，适用于治疗具有化合物结构的JAK介导疾病，其分子式为（I），其中R基在详细描述中有定义。还提供了在人类或动物主体中抑制JAK激酶活性的方法。通过抑制JAK激酶活性治疗的示例疾病包括但不限于炎症性肠病、克罗恩病、溃疡性结肠炎、肠易激综合征和乳糜泻。
• CONDENSED PYRIDINE COMPOUND
  申请人：Shirakami Shohei

  公开号：US20100105661A1

  公开（公告）日：2010-04-29

  The present invention provides a compound having excellent JAK3 inhibitory activity and being useful as an active ingredient of an agent for treating and/or preventing various immune diseases including autoimmune diseases, inflammatory diseases, and allergic diseases. As a result of investigations with respect to novel condensed heterocyclic derivatives, the inventors have verified that a condensed pyridine compound has excellent JAK3 inhibitory activity, thereby completing the present invention. More specifically, it has been verified that since the compound according to the present invention has inhibitory activity against JAK3, the compound is useful as an active ingredient of an agent for treating or preventing diseases caused by undesirable cytokine signal transduction (e.g., rejection during live organ/tissue transplantation, autoimmune diseases, asthma, atopic dermatitis, rheumatism, psoriasis and atherosclerotic disease), or diseases caused by abnormal cytokine signal transduction (e.g., cancer and leukemia).

  本发明提供了一种具有出色JAK3抑制活性的化合物，可作为治疗和/或预防各种免疫疾病，包括自身免疫性疾病、炎症性疾病和过敏性疾病的药剂的有效成分。通过对新型紧缩杂环衍生物的研究，发明人已经验证，紧缩吡啶化合物具有出色的JAK3抑制活性，从而完成了本发明。更具体地说，已经验证，由于本发明的化合物具有对JAK3的抑制活性，因此该化合物可用作治疗或预防由不良细胞因子信号转导引起的疾病（例如，在活体器官/组织移植期间的排斥反应、自身免疫性疾病、哮喘、特应性皮炎、风湿病、牛皮癣和动脉粥样硬化疾病），或由异常细胞因子信号转导引起的疾病（例如癌症和白血病）的有效成分。
• EP2123651
  申请人：——

  公开号：——

  公开（公告）日：——
• EP2420502
  申请人：——

  公开号：——

  公开（公告）日：——